Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG7697 after single subcutaneous administration in healthy subjects
Agnès Portron; Shirin Jadidi; Neena Sarkar; Richard DiMarchi; Christophe Schmitt
Author Information: Department of Clinical Pharmacology, F. Hoffmann‐La Roche AG
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.